中性pH-低葡萄糖降解产物腹膜透析液临床应用进展  

Research progresses in the pH-neutral,low-glucose degradation product dialysates for peritoneal dialysis

作　　者：吴海珊 毛海萍[1,2] 陈崴 阳晓[1] WU Hai-shan;MAO Hai-ping;CHEN Wei;YANG Xiao(Department of Nephrology,the First Affiliated Hospital,Sun Yat-sen University,Ministry of Health,Guangzhou 510080,China;Key Laboratory of Nephrology,Ministry of Health,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院肾内科,广州510080 [2]卫健委和广东省重点实验室,广州510080

出　　处：《中国血液净化》2023年第4期292-295,共4页Chinese Journal of Blood Purification

摘　　要：传统腹膜透析液的高浓度葡萄糖、高葡萄糖降解产物、高糖基化终产物、低pH值等生物不相容性是影响腹膜透析(peritoneal dialysis,PD)疗效、导致PD技术失败的主要原因。中性pH-低葡萄糖降解产物(glucose degradation products,GDP)透析液是一种生物相容性透析液,有研究表明中性pH-低葡萄糖降解产物对终末期肾病患者的影响优于传统腹膜透析液,特别对于长透析患者。因此,本文就中性pH-低GDP腹膜透析液对终末期肾病腹膜透析患者残余肾功能、腹膜功能、腹膜炎发生率、患者生存及技术生存、腹膜结构等方面影响的研究进展进行综述。Conventional glucose-based peritoneal dialysates with higher glucose concentrations,high glucose degradation products,advanced glycation end products and lower pH have been recognized as bio-incompatible,affecting peritoneal dialysis efficacy and leading to technique failure.pH-neutral,lowglucose degradation product dialysates are relatively biocompatible,and are thought to be superior to the conventional dialysates especially in long-term use of peritoneal dialysis.In this paper,we review the recent advances in pH-neutral,low-glucose degradation product dialysates on the residual renal function,peritoneal function,peritonitis rate,patient and technique survival,and peritoneum pathology in peritoneal dialysis patients.

关 键 词：腹膜透析 终末期肾病 中性pH-低葡萄糖降解产物腹膜透析液 

分 类 号：R459.5[医药卫生—治疗学]